Olumiant ® (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

What laboratory tests should be monitored when initiating and continuing treatment with Olumiant® (baricitinib)?

Neutrophil, lymphocyte, hemoglobin, and hepatic transaminases levels should be assessed prior to initiation of baricitinib, and lipids should be assessed 12 weeks after initiation.


Laboratory Monitoring with Baricitinib Treatment 

For information on laboratory monitoring with baricitinb treatment please see  Laboratory measures and monitoring guidance.

 Laboratory measures and monitoring guidance1

Laboratory Measure


Monitoring Guidance


Lipid parameters

Patients should be managed according to international clinical guidelines for hyperlipidaemia

12 weeks after initiation of treatment and thereafter according to international clinical guidelines for hyperlipidaemia

Absolute Neutrophil Count (ANC)

Treatment should be interrupted if ANC

< 1 x 109 cells/L and may be restarted once ANC return above this value





Before treatment initiation and thereafter according to routine patient management

Absolute Lymphocyte Count (ALC)

Treatment should be interrupted if ALC

< 0.5 x 109 cells/L and may be restarted once ALC return above this value


Haemoglobin (Hb)

Treatment should be interrupted if Hb

< 8 g/dL and may be restarted once Hb return above this value

Hepatic transaminases

Treatment should be temporarily interrupted if drug-induced liver injury is suspected

Please refer to section 4.4 of the Olumiant Summary of Product Characteristics for further information on special warnings and precautions for use with baricitinib.


1Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: 08 March 2022

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request